- Q4 2023 Fate Therapeutics Inc Earnings Call TranscriptFeb 26, 2024$6.95 (-0.14%)Earnings
- Q3 2023 Fate Therapeutics Inc Earnings Call TranscriptNov 08, 2023$2.33 (+0.87%)Earnings
- Q2 2023 Fate Therapeutics Inc Earnings Call TranscriptAug 08, 2023$3.53 (-0.56%)Earnings
- Fate Therapeutics Inc at Goldman Sachs Healthcare Conference TranscriptJun 13, 2023
- Fate Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Q1 2023 Fate Therapeutics Inc Earnings Call TranscriptMay 03, 2023$6.32 (+6.76%)Earnings
- Fate Therapeutics Inc at Barclays Global Healthcare Conference TranscriptMar 14, 2023
- Q4 2022 Fate Therapeutics Inc Earnings Call TranscriptFeb 28, 2023$6.12 (+1.83%)Earnings
- Fate Therapeutics Inc at Cowen IO Next Summit (Virtual) TranscriptNov 11, 2022
- Q3 2022 Fate Therapeutics Inc Earnings Call TranscriptNov 03, 2022$19.45 (-2.94%)Earnings
- Fate Therapeutics Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2022
- Q2 2022 Fate Therapeutics Inc Earnings Call TranscriptAug 03, 2022$32.81 (+7.12%)Earnings
- Fate Therapeutics Inc at Bank of America Healthcare Conference TranscriptMay 12, 2022
- Q1 2022 Fate Therapeutics Inc Earnings Call TranscriptMay 04, 2022$30.69 (+6.64%)Earnings
- Fate Therapeutics Inc at Barclays Global Healthcare Conference TranscriptMar 16, 2022
- Q4 2021 Fate Therapeutics Inc Earnings Call TranscriptFeb 28, 2022$34.55 (-1.09%)Earnings
- Fate Therapeutics Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) TranscriptFeb 09, 2022
- Fate Therapeutics Inc Phase 1 FT516 and FT596 Clinical Data Update Call TranscriptDec 14, 2021
- Fate Therapeutics Inc Investor Event - Corporate Call TranscriptNov 15, 2021
- Q3 2021 Fate Therapeutics Inc Earnings Call TranscriptNov 04, 2021$59.65 (-1.21%)Earnings
- Fate Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 10, 2021
- Fate Therapeutics Inc Interim Phase 1 Clinical Data for NHL Programs Call TranscriptAug 19, 2021
- Q2 2021 Fate Therapeutics Inc Earnings Call TranscriptAug 04, 2021$85.73 (+2.98%)Earnings
- Fate Therapeutics Inc at Bank of America NAPA Healthcare Conference TranscriptJun 15, 2021
- Fate Therapeutics Inc Annual Shareholders Meeting TranscriptJun 02, 2021
- Fate Therapeutics Inc at Jefferies Healthcare Conference (Virtual) TranscriptJun 01, 2021
- Fate Therapeutics Inc Interim Phase 1 Clinical Data for AML Programs Corporate Call TranscriptMay 13, 2021
- Q1 2021 Fate Therapeutics Inc Earnings Call TranscriptMay 05, 2021$77.73 (-2.51%)Earnings
- Fate Therapeutics Inc at Barclays Global Healthcare Conference (Virtual) TranscriptMar 11, 2021
- Fate Therapeutics Inc at SVB Leerink Global Healthcare Conference (Virtual) TranscriptFeb 25, 2021
- Q4 2020 Fate Therapeutics Inc Earnings Call TranscriptFeb 24, 2021$95.27 (-0.22%)Earnings
- Q3 2020 Fate Therapeutics Inc Earnings Call TranscriptNov 05, 2020$49.92 (+0.20%)Earnings
- Q2 2020 Fate Therapeutics Inc Earnings Call TranscriptAug 05, 2020$32.84 (+0.67%)Earnings
- Q1 2020 Fate Therapeutics Inc Earnings Call TranscriptMay 11, 2020$30.22 (+4.79%)Earnings
- Q4 2019 Fate Therapeutics Inc Earnings Call TranscriptMar 02, 2020$31.01 (+6.20%)Earnings
- Q3 2019 Fate Therapeutics Inc Earnings Call TranscriptNov 05, 2019$15.71 (+2.68%)Earnings
- Fate Therapeutics, Inc. Presents at Citi's 14th Annual Biotech Conference, Sep-04-2019 01:30 PM TranscriptSep 04, 2019
- Q2 2019 Fate Therapeutics Inc Earnings Call TranscriptAug 06, 2019$19.82 (+2.85%)Earnings
- Q1 2019 Fate Therapeutics Inc Earnings Call TranscriptMay 07, 2019$16.98 (-5.19%)Earnings
- Q4 2018 Fate Therapeutics Inc Earnings Call TranscriptMar 05, 2019$16.03 (-1.05%)Earnings
Fate Therapeutics Inc Phase 1 FT516 and FT596 Clinical Data Update Call Transcript
Good day, and welcome to the Fate Therapeutics ASH Update Call. (Operator Instructions)
As a reminder, this call may be recorded. I would now like to turn the call over to Scott Wolchko. You may begin.
Thank you. Good morning. This is Scott Wolchko, President and CEO of Fate Therapeutics. Thank you all for joining us this morning to discuss our off-the-shelf iPSC-derived NK cell programs, FT516 and FT596, for the treatment of B-cell lymphoma. Please note that during our discussion, our comments will include forward-looking statements that involve risks and uncertainties. These factors are detailed in our SEC filings, and I refer you to the most recent Form 10-Q filed with the SEC on November 4 for full disclosure of these risks and uncertainties. I'm pleased to be joined today by Dr. Wayne Chu, our Senior Vice President of Clinical Development; Dr. Sarah Cooley, our Senior Vice President of Clinical Translation; and Dr. Bob Valamehr, our Chief Research and Development
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)